Author(s): Ranganathan P, Eisen S, Yokoyama WM, McLeod HL
Abstract Share this page
Abstract Methotrexate (MTX) remains the most commonly used disease modifying antirheumatic drug in rheumatoid arthritis (RA) because of its cost and experience in its use, despite the availability of new treatments such as leflunomide and the biological agents. However, a significant number of patients with RA either do not benefit from the drug or are unable to tolerate it. Pharmacogenetic approaches may help optimise treatment with MTX, and also other agents, in RA.
This article was published in Ann Rheum Dis
and referenced in